Hims & Hers Health (NYSE:HIMS) Price Target Cut to $25.00 by Analysts at Morgan Stanley

Posted by Brian Himes on Nov 10th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective reduced by investment analysts at Morgan Stanley from $28.00 to $25.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley‘s price target indicates a potential upside of 33.91% from the company’s previous close.

Several other analysts also recently issued reports on HIMS. TD Cowen lifted their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.57.

Get Our Latest Research Report on Hims & Hers Health

Hims & Hers Health Trading Down 18.6%

Shares of Hims & Hers Health stock traded down $4.27 on Tuesday, reaching $18.67. 35,438,288 shares of the company’s stock were exchanged, compared to its average volume of 22,292,668. The company has a market capitalization of $4.36 billion, a P/E ratio of -29.87 and a beta of 2.53. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $41.28. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The firm’s 50-day moving average is $28.31 and its two-hundred day moving average is $26.91.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 earnings per share. Sell-side analysts predict that Hims & Hers Health will post -0.16 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the transaction, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This represents a 2.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the completion of the transaction, the chief financial officer owned 234,527 shares of the company’s stock, valued at $6,965,451.90. The trade was a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock worth $3,826,977 in the last quarter. Insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of large investors have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Hims & Hers Health in the third quarter worth $37,000. Compass Financial Management LLC purchased a new stake in Hims & Hers Health in the second quarter worth $50,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Hims & Hers Health in the second quarter worth $147,000. Institutional investors own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Q3 revenue rose about 49% year over year to $890.4 million, showing strong business growth. International revenue increased 321%, though the recently acquired Eucalyptus business contributed significantly to that total. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
Neutral Sentiment: Needham kept a Buy rating but cut its price target from $42 to $32, reflecting a more cautious valuation outlook despite its continued endorsement. Article: Needham price target update
Neutral Sentiment: Neuroscientist and health-media personality Andrew Huberman joined the company’s board, adding a prominent health and science voice, though the appointment’s financial impact is uncertain. Article: Andrew Huberman Joins Hims & Hers Board of Directors
Negative Sentiment: Q3 adjusted earnings per share of $0.03 missed analyst estimates of roughly $0.06–$0.07, while revenue also came in slightly below consensus. Article: Q3 Earnings and Revenues Miss Estimates
Negative Sentiment: Management forecast Q4 revenue of $875 million–$895 million, well below the $955.9 million consensus, and FY 2026 revenue of $3.1 billion–$3.2 billion, below the $3.2 billion estimate’s midpoint. The company also cut its FY adjusted EBITDA outlook for the third time this year, to $257 million–$277 million from $300 million–$375 million. Article: Hims & Hers narrows 2026 revenue forecast as margins contract
Negative Sentiment: Gross margin fell to 57.2% from 73.8%, and subscribers declined by 100,000 sequentially to 2.8 million. Those trends, alongside a reported $33 million loss, raise questions about the cost of growth and the durability of customer acquisition. Article: Hims & Hers: Why I’m Not Buying Back Yet

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.